These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18624107)

  • 1. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
    Mrochen-Domin I; Nowara E; Kaleta B
    Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Rossi D; Catalano G
    Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
    [No Abstract]   [Full Text] [Related]  

  • 3. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
    Kanis M; Kesterson JP; Lele S
    Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
    Von Moos R; Cathomas R
    Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
    [No Abstract]   [Full Text] [Related]  

  • 6. Hand-foot syndrome related to liposomal doxorubicin.
    Swenson KK; Bell EM
    Oncol Nurs Forum; 2010 Mar; 37(2):137-9. PubMed ID: 20189920
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
    Molpus KL; Anderson LB; Craig CL; Puleo JG
    Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
    Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
    Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
    Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
    Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
    von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
    Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.
    Zhao Y; Su W; Liang G; Shan X; Ma W; Tang D; Li L; Niu X; Zhao S; Zhang Q; Zhao W
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):63. PubMed ID: 34696815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hand-foot syndrome.
    Pike K
    Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
    [No Abstract]   [Full Text] [Related]  

  • 19. Palmar-plantar erythrodysaesthesia and non-pegylated liposomal doxorubicin. A case study.
    Tamayo-Orbegozo E; Iruin-Sanz A; Oñate-Muzás E; Segrelles-Bellmunt G
    Farm Hosp; 2011; 35(1):46-7. PubMed ID: 20619714
    [No Abstract]   [Full Text] [Related]  

  • 20. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
    Tomb R; Stephan F; Halaby G
    Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.